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Summary
Context Patients with Prader–Willi syndrome (PWS) have an
increased fat mass and decreased lean body mass. GH-treated
young adults with PWS who have attained adult height benefit
from continuation of growth hormone (GH) treatment, as GH
maintained their improved body composition, whereas fat mass
increased during the placebo period. Adults with PWS are pre-
disposed to T2DM and cardiovascular disease. Whether GH
affects metabolic health profile of this patient group is
unknown.
Objective To investigate the effects of GH vs placebo on meta-
bolic health, in young adults with PWS who were GH-treated
for many years during childhood and had attained adult height
(AH).
Method A 2-year, randomized, double-blind, placebo-controlled
crossover study with stratification for gender and BMI in 27
young adults with PWS. Intervention with GH (067 mg/m2/
day) and placebo, both for 1-year duration.
Results Compared to placebo, GH treatment resulted in similar
glucose and insulin levels during oral glucose tolerance test.
Only fasting glucose and insulin were slightly higher during GH
vs placebo (+02 mmol/l and +184 pmol/l), although both
remained within normal ranges in both phases. Blood pressure
and lipid profile were similar after GH vs placebo. At baseline
(AH) and during GH, no patients had metabolic syndrome,
while 1 developed it during placebo treatment.
Conclusions Growth hormone treatment has no adverse
effects on metabolic health profile. Thus, GH-treated young
adults with PWS who have attained AH benefit from continua-
tion of GH treatment without safety concerns regarding meta-
bolic health.
(Received 7 September 2016; returned for revision 16 September
2016; accepted 25 September 2016)
Introduction
Prader–Willi syndrome (PWS) is a neurogenetic disorder caused
by the lack of expression of paternally expressed genes located
on the PWS region of chromosome 15,1,2 with clinical findings
that change over age. Infancy is characterized by muscular hypo-
tonia and failure to thrive, while obesity, hyperphagia, psy-
chomotor delay and behavioural problems are prominent during
childhood and adulthood.3,4 The body composition of patients
with PWS is abnormal, with increased fat mass (FM) and
decreased lean body mass (LBM), even if there is no obesity.2,4–8
In children with PWS, the benefits of growth hormone (GH)
treatment are well-established without adverse effects on glucose
parameters, lipid profile and blood pressure.5 GH improves body
composition, bone mineral density, psychomotor development,
cognition, adaptive functioning, linear growth and adult height
(AH)5,9–12 and has substantially changed the phenotype of chil-
dren with PWS. Currently, when young adults with PWS with-
out GHD have attained AH, they have to discontinue GH
treatment. We recently demonstrated an impressive increase in
FM during the placebo period in GH-treated young adults with
PWS who have attained AH, while continuation of GH main-
tains the improved body composition, indicating that they bene-
fit from continuation of GH treatment.13
Adults with PWS are predisposed to develop type 2 diabetes
mellitus (T2DM) due to their abnormal body composition14 and
cardiovascular disease (CVD), because risk factors for CVD such
as hypertension and hyperlipidaemia occur more often in
PWS.15 GH has diabetogenic effects, but there are no studies on
the metabolic effects of GH vs placebo in young adults with
PWS who were treated with GH during childhood and had
attained AH. Studies in older PWS patients, who were GH-
untreated at inclusion, found no major side effects of GH on
metabolic health profile.16,17
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As there were no negative effects of GH on the metabolic
health profile in GH-treated children and GH-untreated adults
with PWS, we hypothesized that GH vs placebo would result in
a similar or even more favourable metabolic profile after attain-
ment of AH. We therefore investigated the effects of GH vs pla-
cebo on the metabolic health profile of young adults with PWS




Inclusion criteria were (i) genetically confirmed diagnosis of
PWS by a positive methylation test; (ii) GH treatment during
childhood for at least 2 years and being on GH at time of inclu-
sion; and (iii) AH attainment, defined as a height velocity
<05 cm per 6 months and a complete epiphyseal fusion. Exclu-
sion criteria were (i) medication to reduce weight (fat) or (ii)
noncooperative behaviour.
From June 2008 to January 2014, 33 young adults with PWS
aged 141–202 years fulfilled the inclusion criteria, but two did
not want to continue daily injections and three refused to par-
ticipate due to too large a burden of hospital visits. Twenty-
eight subjects were included, but one 167-year-old participant
(BMI 250 kg/m2) died due to gastric rupture 3 months after
the study start while receiving placebo. Her baseline characteris-
tics were not significantly different from the other patients and
were excluded from analysis.
Growth hormone treatment was prescribed during childhood
at an initial dose of 1 mg/m2/day, and the dose was lowered in
eight children due to high serum IGF-I levels. In this study, the
GH dose was 067 mg/m2/day (0023 mg/kg/day), which was
considerably lower than during childhood. The most important
other medications were sex steroid replacement therapy in 12
(429%) young adults, thyroid hormone supplementation in 8
(286%), modafinil in 2 (71%) and risperidone and citalopram
in 1 (36%) adolescent; doses were not changed during the
study. All patients were on strict diet and exercise programmes.
Design
A 2-year, randomized, double-blind, placebo-controlled, cross-
over study investigated the effects of 1-year placebo vs 1-year
GH on metabolic health profile. Young adults were stratified
according to gender and BMI (below/above 25 kg/m2) and then
randomly and blindly assigned to receive 1 year of subcutaneous
injections once daily at bedtime of either 067 mg/m2/day GH
(Genotropin, 5 mg/ml; Pfizer Inc, New York, NY, USA) or
1 year of identical appearing placebo (placebo, Pfizer), after
which they crossed over to the alternative treatment for another
year. According to the FDA, a washout period should be at least
three times the half-life of a drug.18 As the half-life of GH is
only 2–3 h and the study duration per phase was 1 year, no
washout period was implemented. An independent statistician
generated the random allocation sequence. Investigators were
blinded for the allocation. An independent physician monitored
safety during the study. During the entire study period, unblind-
ing was not necessary.
Measurements
Patients were assessed every 3 months by the PWS team of the
Dutch Growth Research Foundation in collaboration with paedi-
atric endocrinologists and paediatricians. At each visit, the injec-
tion dose was adjusted to the calculated body surface area. In
addition, patients visited the Sophia’s Children Hospital at base-
line, 6, 12, 18 and 24 months, to obtain: height, weight, waist
circumference (WC), blood pressure, fasting blood levels of glu-
cose and insulin, total cholesterol (TC), low-density lipoprotein
cholesterol (LDLc) and high-density lipoprotein cholesterol
(HDLc), triglyceride (TG), IGF-I and IGFBP-3. In addition, a
standard 75-g oral glucose tolerance test (OGTT) according to
the World Health Organization was performed. To evaluate the
overall responses to the oral glucose load, apart from the plasma
levels at various time points, the 120-min area under the curve
(AUC) for time–concentration for glucose and insulin was cal-
culated using the trapezoidal rule. The insulin/glucose ratio at 0,
30 and 120 min was calculated as an index of relative insulin
resistance. Impaired glucose tolerance (IGT) was defined as a
fasting glucose level <61 mmol/l, and glucose between 78 and
111 mmol/l (140–200 mg/dl) 120 min after glucose load.19
Standing height was measured with a calibrated Harpenden
stadiometer, weight was determined on a calibrated scale (Servo-
Balance KA-20-150S), and BMI was calculated. Height, weight
and BMI were expressed as SDS, adjusted for age and sex.20,21
SDS values were calculated with GrowthAnalyser 4.0 (www.
growthanalyser.org). Systolic blood pressure (BP) and diastolic
blood pressure (BP) were measured using an appropriately sized
cuff, while patients were in the sitting position. As height is an
important determinant of BP, BP was expressed as standard
deviation scores (SDS), adjusted for height and sex.22 Fat mass
percentage (FM) was measured by DXA.13
Assays
Blood samples were collected after an overnight fast and mea-
sured in a single laboratory: glucose, insulin, IGF-I, IGFBP-3,
TC, HDLc and TG. LDLc was calculated using the Friedewald
formula: LDLc (mmol/l) = TC–HDLc–045*TG.23 Blood samples
during the OGTT for glucose and insulin determination were
obtained after 30, 60, 90 and 120 min after ingestion and imme-
diately assayed.24 Levels of IGF-I and IGFBP-3 were measured
and expressed as SDS, adjusting for age and gender.13,25 Lipids
were determined as described.26
Metabolic syndrome
Revised criteria of the National Cholesterol Education Program
(NCEP; Adult Treatment Panel III) were used to determine
components of the metabolic syndrome.27 Metabolic syndrome
was defined as having three or more of the following risk
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factors: (i) Abdominal obesity: waist circumference in men
>102 cm, and in women >88 cm; (ii) TG above 17 mmol/l;
(iii) HDLc in men below 103, in women below 13 mmol/l; (iv)
BP ≥130/≥85 mm Hg; (v) Fasting glucose above 56 mmol/l.
Statistics
Statistical analysis was performed with SPSS version 23.0 (SPSS
Inc., Chicago, IL, USA). Calculation of sample size based on
body composition indicated that 20 subjects would be sufficient
for a power of >90% with a significance level of 005. To
account for attrition, eight more patients were added. As data
were normally distributed, parametric tests were used and data
expressed as mean [standard deviation (SD)]. Effects of GH vs
placebo were calculated using linear mixed model analysis with
the outcomes measured at the end of the two treatment periods
as dependent variable and with an unstructured covariance
matrix. Possible carry-over effects were analysed by adding the
interaction between period and treatment, but not found. In
addition to the 2-year results, we also presented systolic and
diastolic BP SDS and lipid levels during the 4 years prior to
attainment of adult height, as significant changes in the years
prior to the study might influence the interpretation. Linear
mixed model analysis was used.
Study approval
Written informed consent was obtained from the patients and
their caregivers. The study protocol was approved by the Medi-
cal Ethics Committee of the Erasmus University Medical Center,




Table 1 shows the clinical characteristics of 27 young adults
(eight boys, 19 girls) with PWS at adult height (AH). Their
mean age was 172 (18) years and BMI +09 (13) SDS. Nine
(333%) patients had a deletion, 15 (556%) an mUPD, 2
(74%) an ICD and 1 (37%) a translocation. During childhood,
GH treatment was started at a mean age of 85 (35) years and
continued for 87 (32) years until AH. Boys had a mean AH of
1741 (30) cm, being 14 (04) SDS and girls reached 1599
(73) cm, being 17 (11) SDS. Both treatment regimens had
similar baseline characteristics.
Metabolic health profile
Carbohydrate metabolism. Fig. 1 and Table 2 show glucose and
insulin levels during OGTT after long-term GH treatment
during childhood, at baseline of this study at adult height (AH),
after 1 year of GH and after 1 year of placebo. At baseline, none
of the patients had a fasting glucose above 56 mmol/l, while
IGT, defined as a glucose between 78 and 111 mmol/l at
120 min after glucose load, was present in four patients and
none had T2DM.
Compared to placebo, GH treatment resulted in similar glu-
cose and insulin levels at 30, 60, 90 and 120 min after glucose
load (Fig. 1). Only fasting glucose and insulin levels were higher
after GH treatment vs placebo, although both remained within
the normal ranges in both phases (glucose 47 vs 45 mmol/l,
P = 0012, and insulin 658 vs 474 pmol/l, P = 0037, respec-
tively) (Table 2). All other carbohydrate parameters were similar
after GH vs placebo. Mean glucose at 120 min after glucose
intake was similar (GH vs placebo 60 vs 61 mmol/l,
P = 0998). The 120-min AUCs for glucose and insulin during
OGTT were not significantly different after both treatment
phases (P = 0343 and P = 0457, respectively), and the insulin/
glucose ratios at 30 and 120 min were similar after GH and pla-
cebo. IGT was present in two patients after 1 year of GH and in
two other patients after 1 year of placebo. None of the patients
developed T2DM.
Blood pressure. Fig. 2a,b shows systolic BP and diastolic BP
during the 2-year crossover study and the 4 years before. At
baseline, mean systolic BP and diastolic BP were significantly
higher than height- and sex-matched controls (05 and 07 SDS,
P = 0016 and P < 0001, respectively) (Table 2), but there were
only two patients with a systolic BP above +2 SDS (both +22
SDS).
Compared to placebo, GH treatment resulted in a similar sys-
tolic BP and diastolic BP (P = 0547 and P = 0779). Four
young adults had a systolic BP above +2 SDS after 1 year of
GH, while two of them and one other had an elevated systolic
BP after 1 year of placebo. Two young adults had a diastolic BP
above +2 SDS after both GH and placebo, and 1 only after
1 year of placebo.
Serum lipid levels. Fig. 2c shows fasting serum lipid levels
during the 2-year crossover study and the 4 years before. At
baseline, all mean lipid levels were within the normal range
(Table 2). Levels above the normal range of TC and LDLc were
found in, respectively, two and one patients, while one patient
had a HDLc below the normal range.
Compared to placebo, GH treatment resulted in similar
levels of TC, LDLc, HDLc and TG (P > 0415). One young
adult had a TC above the upper limit of 55 mmol/l after
1 year of GH, while another had an elevated TC after 1 year
of placebo. LDLc and TG were not elevated after 1 year of
GH treatment, while after 1 year of placebo, one patient had
an LDLc higher than the upper limit of 38 mmol/l, and this
and another patient had a TG level higher than 16 mmol/l.
HDLc was not below the lower limit of 09 mmol/l in any
patient.
Metabolic syndrome. Table 3 shows the different components of
the metabolic syndrome (MS). At baseline (AH), none of the
patients had MS according to the revised NCEP criteria.27
After 1 year of GH treatment, 12 components of MS were
present; four patients had central obesity, three low HDLc
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levels and five a high BP, while none had high TG levels or
high fasting glucose. After 1 year of placebo, there were 17
components of MS; five had central obesity, one high TG
levels, six low HDLc levels, four high BP and one a high fasting
glucose.
Compared to placebo, GH treatment did not result in MS.
During the 2 years of study, one girl (37%) developed MS. She
had no MS symptoms after 1 year of GH, but after the subse-
quent year with placebo three symptoms were present.
Discussion
To our knowledge, this is the first 2-year, randomized, dou-
ble-blind, placebo-controlled study in young adults with PWS
who were treated with GH during childhood until AH, which
investigates the effects of GH vs placebo on metabolic health.
Our findings demonstrate that glucose-stimulated glucose and
insulin levels during OGTT were similar during GH treatment
vs placebo. Compared to placebo, GH treatment did not affect
other carbohydrate parameters such as AUC of glucose and
insulin, and insulin/glucose ratios. Fasting glucose and insulin
levels were slightly higher during GH vs placebo therapy, but
remained within the normal ranges during both phases and
none developed T2DM. The prevalence of IGT and MS was
similar after GH treatment and placebo, and BP and lipid
profiles were not significantly different after GH therapy vs
placebo. This indicates that GH does not affect carbohydrate
parameters compared with placebo, with the exception of a
slightly higher fasting glucose and insulin, and that GH
therapy vs placebo does not disturb components of metabolic
health.
Compared to placebo, GH treatment did not affect glucose-
stimulated glucose and insulin levels, AUC for glucose and insu-
lin, and insulin/glucose ratios. These results of the OGTT are
reassuring and demonstrate that glucose and insulin homoeosta-
sis reacts appropriately without developing glucose intolerance
during GH therapy vs placebo. The minor increase in fasting
insulin with minimal influences on glucose metabolism is a
well-known and physiological phenomenon during GH treat-
ment.5,28 Our finding that GH treatment has only minimal
effects without being pathologic concur with the conclusion of
H€oybye et al.16 that GH treatment did not elicit pronounced
adverse effect on glucose and insulin homoeostasis in older pre-
viously GH-untreated adults with PWS.
Lipid levels remained similar during GH vs placebo therapy,
while studies in other patient groups such as GHD or obesity
found beneficial effects of GH treatment on lipid profiles.29,30
Our findings might be the result of the already quite favourable
lipid profile of patients with PWS and the fact that hypercholes-
terolaemia does not seem to be frequent, probably due to the
smaller amount of visceral fat.31 Findings in older adults with
PWS who were GH-untreated at inclusion were in line with our







(n = 14) P*
Boys/girls (n) 8/19 4/9 4/10
Genetic subtype
Deletion 9 7 2
mUPD 15 5 10
ICD/translocation 3 2 1
Age (yrs) 172 (18) 173 (12) 172 (22) 0877
Height for age
(SDS)
13 (09) 12 (09) 13 (09) 0695
Adult height (SDS) 16 (10) 15 (09) 17 (11) 0660
Weight for height
(SDS)
06 (13) 05 (14) 08 (12) 0563
BMI for age (SDS) 09 (13) 07 (13) 10 (12) 0527
BMI for age PWS
(SDS)
14 (12) 15 (12) 12 (12) 0506
Fat mass
percentage (%)
380 (109) 364 (110) 394 (109) 0487
Age at start GH
treatment (yrs)
85 (35) 89 (32) 82 (38) 0646
Duration of GH
treatment (yrs)
87 (32) 84 (25) 89 (38) 0679
Data expressed as mean with (SD).
*P-value at baseline between the two treatment schedules.
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Fig. 1 Glucose and Insulin during oral glucose tolerance test (OGTT).
Mean glucose and insulin levels during OGTT after long-term GH
treatment during childhood at baseline (AH) (black circles), after 1 year
of GH treatment (grey circles) and after 1 year of placebo (white
triangles) of 27 young adults with PWS. #GH vs placebo P-value <005,
¤Baseline vs placebo P-value <005, other not significantly different.
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results,28 although Sode-Carlsen et al.17 reported a small reduc-
tion in LDLc only, during GH therapy compared to placebo.
Their patients were, however, GH-untreated and heavier at base-
line, while our patients had already received 8 years of GH treat-
ment before they participated in the present study, and this
might have influenced the findings.
In our cohort of patients who were GH-treated during child-
hood for many years, none had MS at attainment of AH and
none developed MS during GH therapy after AH, while one
developed MS during placebo treatment. In obese adults with
PWS, a prevalence of MS of 414% was reported, while it was
only 47% in the nonobese PWS subjects.32 The authors con-
cluded that obesity plays a significant role in metabolic health.
Elaborating on this, it might be that the role of body composi-
tion, and subsequently GH treatment, is even larger. Continua-
tion of GH prevents deterioration of body composition13 and
thus favourably affects metabolic health.
Patients with PWS have a relatively high insulin sensitivity
with high adiponectin levels, which are thought to be protective
with regard to T2DM and CVD.31,33–35 Besides the favourable
effects of GH on adiponectin,34 continuation of GH treatment
at AH prevents the deterioration of body composition in young
adults with PWS. During placebo, FM rose dramatically with a
relative increase of 215% in only 1 year, while GH treatment
maintained the improved body composition with less FM and
more LBM.13 Thus, when GH treatment stops, the natural
course of increasing obesity in PWS is no longer counteracted.
As LBM is the primary tissue of insulin-stimulated glucose
uptake, disposal and storage,36 and obesity and FM are associ-
ated with MS, T2DM and CVD,37 it is likely that the deteriora-
tion of body composition due to discontinuation of GH will
impair glucose and insulin homoeostasis over time. This suggests
that discontinuation of GH at AH might result in a worse meta-
bolic health profile in the long term in young adults with PWS,
and that the benefits of GH far outweigh the minimal effects on
glucose and insulin homoeostasis.
The percentage of patients with an mUPD was higher than
previously described,38 but an mUPD is more commonly found
nowadays, probably related to the increasing maternal age at
conception in Western countries. It is not only a diagnosis of
PWS which influences risk of metabolic disease but also other
risk factors such as obesity, advanced age, positive family history
and low LBM. By choosing a crossover design, interindividual
risk factors were eliminated and this strong design allowed a
smaller sample size, especially important as PWS is a rare disor-
der. Ongoing monitoring of young adults with PWS receiving
GH treatment is highly recommended as they are at risk of
developing T2DM and CVD, although our study demonstrated
reassuring findings. Additional studies are needed to confirm
this in the longer term, as our patients are still young and
received only 1 year of GH treatment.
In conclusion, this crossover study demonstrates that 1 year
of GH treatment has no adverse effects on glucose homoeostasis,
with similar glucose-stimulated glucose and insulin levels during
OGTT, AUC of glucose and insulin, and insulin/glucose ratios
during GH treatment and placebo. Fasting glucose and insulin
Table 2. Metabolic health parameters of 27 PWS adolescents at different stages in the study
Stage of the study Mean difference
between GH and
placebo P-value*Baseline After 1 year GH After 1 year placebo
Carbohydrate data
Fasting glucose (mmol/l) 48 (46 to 49) 47 (45 to 49) 45 (43 to 47) 02 0012
AUC glucose (mmol/l*120 min) 897 (824 to 971) 855 (782 to 929) 808 (729 to 887) 47 0343
Fasting insulin (pmol/l) 794 (584 to 1003) 658 (491 to 825) 474 (307 to 641) 184 0037
AUC insulin (pmol/l*120 min*103) 474 (366 to 582) 435 (321 to 548) 394 (277 to 510) 41 0457
Ratio ins/gluc at 30 min 522 (385 to 659) 507 (381 to 633) 412 (282 to 543) 95 0205
Ratio ins/gluc at 120 min 550 (394 to 707) 507 (365 to 650) 535 (381 to 689) 28 0752
Blood pressure
Systolic BP (SDS) 05 (01 to 08) 08 (04 to 11) 06 (03 to 10) 01 0547
Diastolic BP (SDS) 07 (04 to 09) 08 (05 to 11) 09 (06 to 12) 00 0779
Serum lipids
TC (mmol/l) 30 to 55* 44 (41 to 47) 45 (43 to 48) 46 (44 to 48) 00 0851
LDLc (mmol/l) 17 to 38* 27 (24 to 30) 28 (26 to 30) 28 (26 to 30) 00 0711
HDLc (mmol/l) 09 to 19* 15 (13 to 16) 15 (13 to 16) 15 (13 to 16) 00 0974
TG (mmol/l) 04 to 16* 09 (08 to 10) 09 (07 to 10) 08 (07 to 09) 01 0415
Growth factors
IGF-I SDS 22 (17 to 26) 18 (14 to 22) 07 (11 to 03) 25 <0001
IGFBP-3 SDS 05 (02 to 07) 04 (02 to 06) 06 (08 to 03) 10 <0001
GH, growth hormone; AUC, area under the curve; ins/gluc, ratio of insulin/glucose; BP, blood pressure; TC, total cholesterol; TG, triglyceride; PWS,
Prader–Willi syndrome.
Data expressed as mean with 95% CI.
*Normal range for 13–18 years. P-value of mean difference between GH and placebo, bold values are statistically significant (p<0.05).
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levels remained within the normal ranges and were only slightly
higher during GH treatment vs placebo. Blood pressure and
lipid profile remained similar in both phases. None of the
patients developed MS during GH treatment, while one devel-
oped MS during placebo. Thus, GH-treated young adults with
PWS who have attained AH benefit from continuation of GH
treatment without safety concerns regarding their metabolic
health profile.
Acknowledgements
We express our gratitude to all young adults and parents
for their enthusiastic participation in this study. We thank
Mari€elle van Eekelen, Berber Kerkhof and Elise Snikkers for
their help. We thank all the collaborating physicians and the
paediatricians who referred patients to participate in our
study.
Funding
This study was an investigator-initiated study, supported by an
independent research grant from Pfizer. Pfizer provided Geno-
tropin and identical appearing placebo without charge.
Declaration of interest
The study was investigator-initiated, ACH received an indepen-
dent research grant from Pfizer. The other authors have declared
that no conflict of interest exists.
References
1 Goldstone, A.P., Holland, A.J., Hauffa, B.P. et al. (2008) Recom-
mendations for the diagnosis and management of Prader–Willi
syndrome. Journal of Clinical Endocrinology and Metabolism, 93,
4183–4197.
2 Cassidy, S.B. (1997) Prader–Willi syndrome. Journal of Medical
Genetics, 34, 917–923.
Placebo/GH 0·67 mg/m2 Placebo/GH 0·67 mg/m2GH 1·0 mg/m2






Placebo/GH 0·67 mg/m2 Placebo/GH 0·67 mg/m2GH 1·0 mg/m2






Placebo/GH 0·67 mg/m2 Placebo/GH 0·67 mg/m2GH 1·0 mg/m2










Systolic blood pressure (SDS)





Fig. 2 (a–c) Changes in systolic (a) and diastolic blood pressure (b), and
total cholesterol, LDLc and HDLc (c) presented as Means with 95% CI
of 27 adolescents with PWS during the 2 years of this crossover study
(in dark and light grey). Longitudinal changes in Estimated Marginal
Means with 95% CI during the 4 years prior to attainment of AH (in
white). BP SDS was calculated according to height- and sex-matched
references.22 Normal ranges for lipids are shown on the right side of
Fig. 2c. Black lines with black symbols represent the course during GH
treatment, and dotted lines with white symbols represent the course
during placebo.
Table 3. Metabolic syndrome components during the study according to
ATP III criteria26
Symptoms







Central Obesity 2/27 (74%) 4/27 (148%) 5/27 (185%)
High TG levels None None 1/27 (37%)
Low HDLc levels 6/27 (222%) 3/27 (111%) 6/27 (222%)
High BP 3/27 (111%) 5/27 (185%) 4/27 (148%)
High fasting
glucose
None None 1/27 (37%)
More than 3
symptoms
None None 1/27 (37%)
GH, growth hormone; TG, triglyceride; BP, blood pressure.
Number of patients (%) with MS symptoms. No significant difference
between GH and placebo year.
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
Clinical Endocrinology (2017), 86, 297–304
302 R. J. Kuppens et al.
3 Eiholzer, U., Bachmann, S. & l’Allemand, D. (2000) Is there
growth hormone deficiency in Prader–Willi Syndrome? Six argu-
ments to support the presence of hypothalamic growth hormone
deficiency in Prader–Willi syndrome. Hormone Research, 53
(Suppl 3), 44–52.
4 Holm, V.A., Cassidy, S.B., Butler, M.G. et al. (1993) Prader–Willi
syndrome: consensus diagnostic criteria. Pediatrics, 91, 398–402.
5 Bakker, N.E., Kuppens, R.J., Siemensma, E.P. et al. (2013) Eight
years of growth hormone treatment in children with Prader–
Willi syndrome: maintaining the positive effects. Journal of Clini-
cal Endocrinology and Metabolism, 98, 4013–4022.
6 Emerick, J.E. & Vogt, K.S. (2013) Endocrine manifestations and
management of Prader–Willi syndrome. International Journal of
Pediatric Endocrinology, 2013, 14.
7 Brambilla, P., Bosio, L., Manzoni, P. et al. (1997) Peculiar body
composition in patients with Prader-Labhart-Willi syndrome.
American Journal of Clinical Nutrition, 65, 1369–1374.
8 Bekx, M.T., Carrel, A.L., Shriver, T.C. et al. (2003) Decreased
energy expenditure is caused by abnormal body composition in
infants with Prader–Willi Syndrome. Journal of Pediatrics, 143,
372–376.
9 Bakker, N.E., Kuppens, R.J., Siemensma, E.P. et al. (2015) Bone
mineral density in children and adolescents with Prader–Willi
syndrome: a longitudinal study during puberty and 9 years of
growth hormone treatment. Journal of Clinical Endocrinology and
Metabolism, 100, 1609–1618.
10 Festen, D.A., Wevers, M., Lindgren, A.C. et al. (2008) Mental
and motor development before and during growth hormone
treatment in infants and toddlers with Prader–Willi syndrome.
Clinical Endocrinology, 68, 919–925.
11 Siemensma, E.P., Tummers-de Lind van Wijngaarden, R.F., Fes-
ten, D.A. et al. (2012) Beneficial effects of growth hormone
treatment on cognition in children with Prader–Willi syndrome:
a randomized controlled trial and longitudinal study. Journal of
Clinical Endocrinology and Metabolism, 97, 2307–2314.
12 Lo, S.T., Festen, D.A., Tummers-de Lind van Wijngaarden, R.F.
et al. (2015) Beneficial effects of long-term growth hormone
treatment on adaptive functioning in infants with Prader–Willi
syndrome. American Journal on Intellectual Developmental Dis-
abilities, 120, 315–327.
13 Kuppens, R.J., Bakker, N.E., Siemensma, E.P.C. et al. (2016) Bene-
ficial effects of growth hormone in young adults with Prader–Willi
syndrome: results of a 2-year randomized, double-blind, placebo-
controlled cross-over trial. Journal of Clinical Endocrinology and
Metabolism, 101, 4110–4116.
14 Nagai, T. & Mori, M. (1999) Prader–Willi syndrome, diabetes
mellitus and hypogonadism. Biomedicine & Pharmacotherapy, 53,
452–454.
15 Laurier, V., Lapeyrade, A., Copet, P. et al. (2015) Medical, psy-
chological and social features in a large cohort of adults with
Prader–Willi syndrome: experience from a dedicated centre in
France. Journal of Intellectual Disability Research, 59, 411–421.
16 Hoybye, C., Hilding, A., Jacobsson, H. et al. (2003) Growth hor-
mone treatment improves body composition in adults with
Prader–Willi syndrome. Clinical Endocrinology, 58, 653–661.
17 Sode-Carlsen, R., Farholt, S., Rabben, K.F. et al. (2010) One year
of growth hormone treatment in adults with Prader–Willi syn-
drome improves body composition: results from a randomized,
placebo-controlled study. Journal of Clinical Endocrinology and
Metabolism, 95, 4943–4950.
18 Senn, S. (1994) The AB/BA crossover: past, present and future?
Statistical Methods in Medical Research, 3, 303–324.
19 World Health Organization (2006) Definition and Diagnosis of
Diabetes Mellitus and Intermediate Hyperglycemia: Report of a
WHO/IDF Consultation. World Health Organization.
20 Fredriks, A.M., van Buuren, S., Wit, J.M. et al. (2000) Body
index measurements in 1996–7 compared with 1980. Archives of
Disease in Childhood, 82, 107–112.
21 Fredriks, A.M., van Buuren, S., Burgmeijer, R.J. et al. (2000)
Continuing positive secular growth change in The Netherlands
1955–1997. Pediatric Research, 47, 316–323.
22 Rosner, B., Prineas, R.J., Loggie, J.M. et al. (1993) Blood pres-
sure nomograms for children and adolescents, by height, sex,
and age, in the United States. Journal of Pediatrics, 123, 871–886.
23 Friedewald, W.T., Levy, R.I. & Fredrickson, D.S. (1972) Estima-
tion of the concentration of low-density lipoprotein cholesterol
in plasma, without use of the preparative ultracentrifuge. Clinical
Chemistry, 18, 499–502.
24 Kuppens, R.J., Diene, G., Bakker, N.E. et al. (2015) Elevated
ratio of acylated to unacylated ghrelin in children and young
adults with Prader–Willi syndrome. Endocrine, 50, 633–642.
25 Rikken, B., van Doorn, J., Ringeling, A. et al. (1998) Plasma
levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-bind-
ing protein-3 in the evaluation of childhood growth hormone
deficiency. Hormone Research, 50, 166–176.
26 van der Steen, M., Lem, A.J., van der Kaay, D.C. et al. (2015)
Metabolic health in short children born small for gestational age
treated with growth hormone and gonadotropin-releasing hor-
mone analog: results of a randomized, dose-response trial. Jour-
nal of Clinical Endocrinology and Metabolism, 100, 3725–3734.
27 Grundy, S.M., Cleeman, J.I., Daniels, S.R. et al. (2005) Diagnosis
and management of the metabolic syndrome: an American Heart
Association/National Heart, Lung, and Blood Institute Scientific
Statement. Circulation, 112, 2735–2752.
28 Sanchez-Ortiga, R., Klibanski, A. & Tritos, N.A. (2012) Effects of
recombinant human growth hormone therapy in adults with
Prader–Willi syndrome: a meta-analysis. Clinical Endocrinology,
77, 86–93.
29 Maison, P., Griffin, S., Nicoue-Beglah, M. et al. (2004) Impact
of growth hormone (GH) treatment on cardiovascular risk fac-
tors in GH-deficient adults: a Metaanalysis of Blinded, Random-
ized, Placebo-Controlled Trials. Journal of Clinical Endocrinology
and Metabolism, 89, 2192–2199.
30 Mekala, K.C. & Tritos, N.A. (2009) Effects of recombinant
human growth hormone therapy in obesity in adults: a meta
analysis. Journal of Clinical Endocrinology and Metabolism, 94,
130–137.
31 Talebizadeh, Z. & Butler, M.G. (2005) Insulin resistance and
obesity-related factors in Prader–Willi syndrome: comparison
with obese subjects. Clinical Genetics, 67, 230–239.
32 Grugni, G., Crino, A., Bedogni, G. et al. (2013) Metabolic syn-
drome in adult patients with Prader–Willi syndrome. Nutrition,
Metabolism and Cardiovascular Diseases, 23, 1134–1140.
33 Zipf, W.B. (1999) Glucose homeostasis in Prader–Willi syn-
drome and potential implications of growth hormone therapy.
Acta Paediatrica. Supplement, 88, 115–117.
34 Festen, D.A., van Toorenenbergen, A., Duivenvoorden, H.J. et al.
(2007) Adiponectin levels in prepubertal children with Prader–
Willi syndrome before and during growth hormone therapy.
Journal of Clinical Endocrinology and Metabolism, 92, 1549–1554.
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
Clinical Endocrinology (2017), 86, 297–304
Metabolic health and GH in young adults with PWS 303
35 Pagano, C., Marin, O., Calcagno, A. et al. (2005) Increased
serum resistin in adults with Prader–Willi syndrome is related to
obesity and not to insulin resistance. Journal of Clinical
Endocrinology and Metabolism, 90, 4335–4340.
36 Smith, A.G. & Muscat, G.E. (2005) Skeletal muscle and nuclear
hormone receptors: implications for cardiovascular and meta-
bolic disease. International Journal of Biochemistry & Cell Biology,
37, 2047–2063.
37 Mokdad, A.H., Ford, E.S., Bowman, B.A. et al. (2003) Prevalence
of obesity, diabetes, and obesity-related health risk factors, 2001.
JAMA, 289, 76–79.
38 Angulo, M.A., Butler, M.G. & Cataletto, M.E. (2015) Prader–
Willi syndrome: a review of clinical, genetic, and endocrine
findings. Journal of Endocrinological Investigation, 38, 1249–
1263.
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
Clinical Endocrinology (2017), 86, 297–304
304 R. J. Kuppens et al.
